Inactive Instrument

CannPal Animal Therapeutics Limited

Equities

CP1

AU000000CP17

Biotechnology & Medical Research

Cannpal Animal Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2019

August 30, 2019 at 01:14 am EDT

CannPal Animal Therapeutics Limited announced earnings results for the full year ended June 30, 2019. For the full year, the company announced total revenue was AUD 400,879 compared to AUD 205,912 a year ago. Net loss was AUD 2.007 million compared to AUD 1.694 million a year ago.

Latest news about CannPal Animal Therapeutics Limited

Layton Mills and Margaret Curtis agreed to acquire 52% stake in CannPal Animal Therapeutics Limited from AusCann Group Holdings Ltd for AUD1.	23-03-09	CI
AusCann Group Holdings Ltd completed the acquisition of CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others.	21-03-10	CI
Cannpal Animal Therapeutics : Narrows Fiscal H1 Loss on Higher Revenue	21-02-19	MT
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2020	21-02-18	CI
AusCann : CannPal Managing Director to Lead Merged Company Formed With AusCann; CannPal Rises 11%	21-01-07	MT
AusCann Group Holdings Ltd entered into a scheme implementation deed to acquire CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others for AUD 16.9 million.	20-11-15	CI
CannPal Animal Therapeutics Limited Announces Resignation of Max Johnston as Non-Executive Director	20-08-28	CI
CannPal Animal Therapeutics Limited Announces Completion of its Safety and Efficacy Study for DermaCann	20-07-20	CI
CannPal Animal Therapeutics Limited Announces FDA Establishes Investigational New Animal Drug file for CPAT-01	20-03-10	CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2019	20-02-25	CI
CannPal Animal Therapeutics Limited Enters into Exclusive Licensing Agreement with Commonwealth Scientific and Industrial Research Organisation	20-01-05	CI
49,365,405 Ordinary Shares of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.	19-10-24	CI
2,000,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.	19-10-24	CI
625,000 Class A Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.	19-10-24	CI
1,500,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.	19-10-24	CI
7,250,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.	19-10-24	CI
625,000 Class B Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.	19-10-24	CI
625,000 Class C Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.	19-10-24	CI
625,000 Class D Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.	19-10-24	CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2019	19-08-30	CI
CannPal Animal Therapeutics Limited Commences Phase 2 Pilot Study for Cannabis-Derived Osteoarthritis Drug for Dogs	19-07-31	CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2018	19-02-25	CI
CannPal Animal Therapeutics Limited Receives Key Ethics Approvals for CPAT-01 Phase 2A Study and Dermacann Skin Study	19-02-12	CI
Cannpal Animal Therapeutics Limited Completes Phase 1B Cannabinoid Study in Dogs	18-12-11	CI
Cannpal Animal Therapeutics Limited Receives US FDA Sponsor Fee Waiver for Lead Drug Candidate CPAT-01	18-09-23	CI

Chart CannPal Animal Therapeutics Limited

Duration

Period

Chart CannPal Animal Therapeutics Limited

More charts

Company Profile

CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The Company is focused on research, developing and commercializing therapeutics for the companion animal health industry, using the compounds derived from the cannabis plants. It is focused on cats and dogs. Its lead drug candidate is CPAT-01, which targets osteosarcoma pain in dogs. It is also engaged in investigating and researching the ability to use cannabidiol derived from the hemp plant for developing a nutraceutical range of products for use in companion animals, including dogs, cats, birds, horses and other domestic animals, without a prescription. It is also developing pharmaceutical therapeutics for chronic pain and appetite stimulation. It is developing nutraceutical products for skin conditions, joint health and digestive health.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs